Seattle Genetics highlights Ab-drug conjugate programs

Washington, USA-based Seattle Genetics has announced data highlighting preclinical findings on two of its antibody-drug conjugate programs, SGN-35 and SGN-19A, as well as research advances with its proprietary ADC technology. The data were being presented at the European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research International Conference on Molecular Targets and Cancer Therapeutics being held in Geneva, Switzerland.

"Our ADC technology is gaining substantial momentum, demonstrated by the four empowered antibodies now in clinical trials between us and our collaborators, as well as progress with multiple preclinical programs," said Clay Siegall, chief executive of the firm. "Data presented on SGN-19A, our anti-CD19 ADC, suggest it may represent a promising addition to the treatment options for non-Hodgkin's lymphoma and other hematologic malignancies, including acute lymphoblastic leukemia. In addition, preclinical research with SGN-35 demonstrates its utility in a variety of Hodgkin's lymphoma settings, including in combination with upfront and salvage chemotherapy regimens, complementing our clinical data on its ability to induce objective responses as a single agent," he added.

Data summary